Skip to main content

Smith Beth Ann's Form 4 filing

Macrogenics Inc (MGNX) · filed Feb 19, 2025

Accession no.
0001125345-25-000031
Filed
Feb 19, 2025
Trade date
Feb 15, 2025
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.08K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Smith Beth AnnCIK 0002051299Officer (VP, Controller & Treasurer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 15, 2025Common StockMOption exerciseAcquired+1,095$0.00F1$09,955Direct
Feb 15, 2025Common StockSSaleDisposed−423$2.56−$1,082.889,532Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 15, 2025Common StockMOption exerciseDisposed−1,095$0.00$01,095Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On February 15, 2023 the reporting person was granted 3,285 restricted stock units, 33% of which vested on February 15, 2024 and 33% of which will vest each year thereafter. Restricted stock units convert into the Company's stock on a one-for-one basis.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)